21,400
employees
150
Over 150 COUNTRIES
in which the Group’s
medicines are distributed
20%
Over 20% of revenue from
brand-name medicines invested
in R&D each year
€ 4.9 billion
euros in revenue in 2021/2022
including €3.7 billion for brand-name medicines
and €1.2 billion for generic activities
5 therapeutic areas
Neuropsychiatry, Venous diseases,
Cardiovascular, Diabetes
and Oncology